Currently, there are 70.68M common shares owned by the public and among those 70.48M shares have been available to trade.
The company’s stock has a 5-day price change of 9.09% and 11.18% over the past three months. ALT shares are trading -38.13% year to date (YTD), with the 12-month market performance up to 184.08% higher. It has a 12-month low price of $2.09 and touched a high of $14.84 over the same period. ALT has an average intraday trading volume of 3.27 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.55%, 4.68%, and -12.12% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Altimmune Inc (NASDAQ: ALT) shares accounts for 60.20% of the company’s 70.68M shares outstanding.
It has a market capitalization of $494.65M and a beta (3y monthly) value of 0.12. The earnings-per-share (ttm) stands at -$1.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.89% over the week and 6.93% over the month.
Analysts forecast that Altimmune Inc (ALT) will achieve an EPS of -0.36 for the current quarter, -0.33 for the next quarter and -1.47 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.41 while analysts give the company a high EPS estimate of -0.41. Comparatively, EPS for the current quarter was -0.39 a year ago. Earnings per share for the fiscal year are expected to increase by 16.61%, and -9.49% over the next financial year.
Goldman coverage for the Altimmune Inc (ALT) stock in a research note released on January 24, 2024 offered a Neutral rating with a price target of $13. Goldman was of a view on March 22, 2023 that the stock is Neutral, while Goldman gave the stock Buy rating on December 01, 2022, issuing a price target of $20. Jefferies on their part issued Buy rating on December 29, 2021.
